ClinicalTrials.gg
RecruitingNCT06941870SYNOVIIIUSUpdated Nov 9, 2026

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

A Phase 4 interventional study of Efanesoctocog alfa in Factor VIII Deficiency, sponsored by Sanofi. Recruiting at 19 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Nov 9, 2026First site in AustraliaSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing efanesoctocog alfa in Hemophilia A — 1 open to participants now, 5 under way, 2 of them phase 3. efanesoctocog alfa · Hemophilia A.

Planned enrollment
8th of 11
35 · median 74
Started
2025
with 3 others
Phase 4
3 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
2 of 11
Sanofi

Among the 11 studies testing efanesoctocog alfa in Hemophilia A, this one is the 8th largest by planned enrollment, is one of 4 that started in 2025, is one of 3 in phase 4, and was the 10th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 11 studies testing efanesoctocog alfa in Hemophilia A is open now, in 5 countries.

By country, each count listing its studies:

About efanesoctocog alfa

efanesoctocog alfa: first FDA approval 2023 (ALTUVIIIO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing efanesoctocog alfa in Hemophilia A, or all of them as a file.
02

Study summary

The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A.

The study duration for each participant is approximately 12 months.

03

Conditions studied

  • Factor VIII Deficiency

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is diagnosed with moderate to severe hemophilia A (defined as less than or equal to (≤)5 percent (%) of endogenous FVIII clotting activity) at the time of consent/assent.
  • Participant is more than or equal to (≥)12 years old at the time of consent/assent.
  • Participant has existing synovial hypertrophy, defined as at least 1 eligible* joint by the HEAD-US score (Synovitis score: 1 or 2) at the time of consent/assent.
  • Participant has at least 1 eligible* joint without planned future major orthopedic procedures (example, arthroscopic synovectomy, radioisotopic or chemical synoviorthesis), or major orthopedic procedures in the past 3 months prior to the screening visit (Visit 1).

    *An eligible joint is a joint with existing synovial hypertrophy, as defined by a HEAD-US synovitis score of 1 or 2, considering hypertrophic synovium as an indication of the presence of synovitis

  • Participant has received prophylactic treatment with hemophilia prophylaxis prescriptions in the last 12 months prior to the baseline visit (Visit 2).
  • Participant is capable of understanding the written Form (ICF)/assent form, provides a signed and witnessed written ICF/assent form, and agrees to comply with the protocol requirements.
  • If male, no measures are required for this study.
  • If female, is not pregnant or breastfeeding, and one of the following conditions applies:
  • Is a women of nonchildbearing potential (WONCBP)
  • Is a and agrees to use a highly effective contraceptive method, with a failure rate of less than (\<)1 percent during the study treatment period (at least until the Week 52/ End of Treatment [EoT] visit).
  • A WOCBP must have a negative serum pregnancy test at the screening visit (Visit 1)

Exclusion criteria

Exclusion Criteria:

  • Participants are excluded from the study if any of the following criteria apply:
  • Has other associated clotting disorders at the time of consent/assent.
  • Is already under efanesoctocog alfa treatment.
  • Has a current diagnosis of an factor VIII (FVIII) inhibitor, defined as inhibitor titer ≥0.60 BU/mL.
  • Has ITI within the last 2 years prior to the baseline visit (Visit 2).
  • Has been enrolled in a concurrent clinical interventional study or exposed to other drug(s) within 3 months prior to screening for this study.
  • Is currently in an institution because of regulatory or legal order (that is, is a prisoner or a patient who is legally institutionalized).
  • Is not suitable for participation, whatever the reason, as judged by the investigator, including medical or clinical conditions, or patients potentially at risk of noncompliance to study procedures.
  • Is an employee or family member of the investigator or site personnel.
  • Is involved in a specific situation during study implementation or the course of the study that may raise ethics considerations.
  • Has to efanesoctocog alfa or its components or any of its that, in the opinion of the investigator, contraindicates participation in the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Efanesoctocog Alfa

    Participants will receive Efanesoctocog Alfa at 50 international unit per kilogram (IU/kg) intravenous (IV) QW

    Drug: Efanesoctocog alfa

Interventions

  • Pharmaceutical form:Lyophilized powder in a sterile vial that requires reconstitution with sterile water for injection (diluent)-Route of administration:Intravenous

    Also known as: BIVV001, ALTUVIIIO®

06

What researchers measure

Primary outcomes

  1. Proportion of joints with improvement in the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovitis domain score

    HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

    Time frame: From Baseline up to Week 52

Secondary outcomes

  1. Change from baseline in the distribution of joint HEAD-US synovitis score

    HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

    Time frame: From Baseline up to Week 52

  2. Number of joints with the HEAD-US synovitis domain score that has remained unchanged or worsened

    HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

    Time frame: From Baseline up to Week 52

  3. Percentage of joints with the HEAD-US synovitis domain score that has remained unchanged or worsened

    HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

    Time frame: From Baseline up to Week 52

  4. Number of index joint type with the HEAD-US synovitis domain score that has improved, remained unchanged, or worsened

    HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

    Time frame: From Baseline up to Week 52

  5. Percentage of index joint type with the HEAD-US synovitis domain score that has improved, remained unchanged, or worsened

    HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

    Time frame: From Baseline up to Week 52

  6. Number of participants with at least 1 joint with the HEAD-US synovitis domain score that has improved, remained unchanged, or worsened

    HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

    Time frame: From Baseline up to Week 52

  7. Percentage of participants with at least 1 joint with the HEAD-US synovitis domain score that has improved, remained unchanged, or worsened

    HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

    Time frame: From Baseline up to Week 52

  8. Change from baseline in average HEAD-US synovitis domain score across all index joints

    HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

    Time frame: From Baseline up to Week 52

  9. Change from baseline in total/ domain scores of the HEAD-US

    HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

    Time frame: From Baseline up to Week 26

  10. Change from baseline in total/domain scores of the HJHS

    HJHS comprises an assessment of specific features, or items, of the 6 index joints and an assessment of global gait. For each of the 6 joints, the following items are scored: swelling (0 to 3), duration of swelling (0 to 1), muscle atrophy (0 to 2), crepitus on motion (0 to 2), flexion loss (0 to 3), extension loss (0 to 3), joint pain (0 to 2), and strength (0 to 4). The maximum score for an individual index joint is 20. Gait is scored from 0 to 4. The maximum HJHS total score is 124, with a higher score indicating worse joint health.

    Time frame: From Baseline up to Week 26

  11. Change from baseline in total/domain scores of the HJHS

    HJHS comprises an assessment of specific features, or items, of the 6 index joints and an assessment of global gait. For each of the 6 joints, the following items are scored: swelling (0 to 3), duration of swelling (0 to 1), muscle atrophy (0 to 2), crepitus on motion (0 to 2), flexion loss (0 to 3), extension loss (0 to 3), joint pain (0 to 2), and strength (0 to 4). The maximum score for an individual index joint is 20. Gait is scored from 0 to 4. The maximum HJHS total score is 124, with a higher score indicating worse joint health.

    Time frame: From Baseline up to Week 52

  12. Change from baseline in total/ domain scores of magnetic resonance imaging (MRI)

    MRI will be used to detect changes in synovial hypertrophy in index joints of participants.

    Time frame: From Baseline up to Week 52

  13. Change from baseline in patient-reported outcome (PRO)

    Change from baseline in PRO will be assessed by the EQ-5D 5-level (EQ-5D-5L), Patient-Reported Outcomes Measurement Information System - Short Form (PROMIS-SF) version 2.0 Pain Intensity 3a, PROMIS-SF version 1.1 Pain Interference 6a, and PROMIS-SF version 2.0 Physical Function 6b.

    Time frame: From Baseline up to Week 52

  14. Patient reported treatment preference and satisfaction

    Patient reported treatment preference and satisfaction will be assessed through surveys and exit interviews.

    Time frame: At Week 52

  15. Change from baseline in annualized bleeding rate (ABR) (spontaneous, traumatic)

    The ABR will be defined as (number of bleeding episodes occurring during the treatment period)/(duration of the treatment period \[days\]) × 365.25.

    Time frame: At Week 52

  16. Change from baseline in annualized joint bleeding rate (AjBR) (spontaneous, traumatic)

    The AjBR will be defined as (number of joint bleeding episodes occurring during the treatment period)/(duration of the treatment period \[days\]) × 365.25.

    Time frame: At Week 52

  17. Change from baseline in target joint resolution, recurrence, or development

    Change from baseline in target joint resolution, recurrence, or development will be assessed.

    Time frame: At Week 52

  18. The occurrence of Adverse Events (AEs), all AEs leading to treatment discontinuation, Serious Adverse Events (SAEs), and Adverse Event of Special Interest (AESIs)

    The safety and tolerability of efanesoctocog alfa evaluated in all participants

    Time frame: Up to Week 52

07

Study locations

13 of 19 sites recruiting
  • Orthopedic Institute for Children- Site Number : 8400009
    Los Angeles, California 90007, United States
    Completed

    Not enrolling at this site.

  • University of California Davis Medical Center-Site Number: 8400005
    Sacramento, California 95817-1399, United States
    Recruiting
  • Indiana Hemophilia and Thrombosis Center- Site Number : 8400006
    Indianapolis, Indiana 46260, United States
    Recruiting
  • University of Iowa- Site Number : 8400004
    Iowa City, Iowa 52242, United States
    Recruiting
  • The Ohio State University Wexner Medical Center - CarePoint East- Site Number : 8400001
    Columbus, Ohio 43203, United States
    Completed

    Not enrolling at this site.

  • Oregon Health and Science University-Site Number: 8400002
    Portland, Oregon 97239-3011, United States
    Recruiting
  • Washington Center for Bleeding Disorders- Site Number : 8400008
    Seattle, Washington 98101-3932, United States
    Recruiting
  • Investigational Site Number : 0360001
    Murdoch, Western Australia 6150, Australia
    Completed

    Not enrolling at this site.

  • Investigational Site Number : 1240002
    Calgary, Alberta T2N 1N4, Canada
    Recruiting
  • Investigational Site Number : 1240001
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
    Recruiting
  • Investigational Site Number : 1240003
    Hamilton, Ontario L8N 3Z5, Canada
    Recruiting
  • Investigational Site Number : 1240004
    Hamilton, Ontario L8N 3Z5, Canada
    Completed

    Not enrolling at this site.

  • Investigational Site Number : 3920003
    Kawasaki, Kanagawa 216-8511, Japan
    Recruiting
  • Investigational Site Number : 3920002
    Hiroshima, 734-8551, Japan
    Completed

    Not enrolling at this site.

  • Investigational Site Number : 3920001
    Saitama, 330-8777, Japan
    Recruiting
  • Investigational Site Number : 3920004
    Tokyo, 160-0023, Japan
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 1580003
    Kaohsiung City, 80756, Taiwan
    Recruiting
  • Investigational Site Number: 1580001
    Taichung, 407, Taiwan
    Recruiting
  • Investigational Site Number: 1580002
    Taipei, 114, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Oct 2027, 25 months after the start.

Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
Apr 24, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Oct 25, 2027
CompletionEst.
Oct 25, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added, 5 sites removed — first site in Australia. 4 sites changed recruiting status (4 now completed)
Show 4 sites
  • Orthopedic Institute for Children- Site Number : 8400009 · Los Angeles, United StatesRecruiting→Completed
  • Investigational Site Number : 1240004 · Hamilton, CanadaRecruiting→Completed
  • Investigational Site Number : 3920002 · Hiroshima, JapanRecruiting→Completed
  • Investigational Site Number : 3920004 · Tokyo, JapanRecruiting→Completed
Show 11 added (5 United States, 3 Taiwan, 2 Canada, 1 Australia)
  • Indiana Hemophilia and Thrombosis Center- Site Number : 8400006 · Indianapolis, United States
  • The Ohio State University Wexner Medical Center - CarePoint East- Site Number : 8400001 · Columbus, United States
  • Washington Center for Bleeding Disorders- Site Number : 8400008 · Seattle, United States
  • Investigational Site Number: 1580003 · Kaohsiung City, Taiwan
  • Investigational Site Number: 1580001 · Taichung, Taiwan
  • Investigational Site Number: 1580002 · Taipei, Taiwan
  • University of California Davis Medical Center-Site Number: 8400005 · Sacramento, United States
  • Oregon Health and Science University-Site Number: 8400002 · Portland, United States
  • Investigational Site Number : 0360001 · Murdoch, Australia
  • Investigational Site Number : 1240002 · Calgary, Canada
  • Investigational Site Number : 1240001 · St. John's, Canada
Show 5 removed
  • Innovative Hematology, Inc.- Site Number : 8400006 · Indianapolis, United States
  • Ohio State University Hospital East- Site Number : 8400001 · Columbus, United States
  • Investigational Site Number : 1580003 · Kaohsiung City, Taiwan
  • Investigational Site Number : 1580001 · Taichung, Taiwan
  • Investigational Site Number : 1580002 · Taipei, Taiwan
across 2 updates, Oct 15, 2026 – Nov 9, 2026
Eligibility
4 inclusion criteria edited, 2 added; 3 exclusion criteria edited, 6 added
What changed in the criteria
Inclusion criteria
  • EditedInclusion Criteria: Participant is diagnosed with moderate to severe hemophilia A (defined as less than or equal to (≤)5 percent (%) of endogenous FVIII clotting activity) at the time of consent/assent.
  • Edited*An eligible joint is a joint with existing synovial hypertrophy, as defined by a HEAD-US synovitis score of 1 or 2, considering hypertrophic synovium as an indication of the presence of synovitis Participant has received prophylactic treatment with hemophilia prophylaxis prescriptions in the last 12 months prior to the baseline visit (Visit 2).
  • AddedParticipant has received prophylactic treatment with hemophilia prophylaxis prescriptions in the last 12 months prior to the baseline visit (Visit 2).
  • AddedIs a women of nonchildbearing potential (WONCBP)
  • EditedIs a women of nonchildbearing potential (WONCBP) Is a women of childbearing potential (WOCBP) and agrees to use a highly effective contraceptive method, with a failure rate of less than (<)1 percent during the study treatment period (at least until the Week 52/ End of Treatment [EoT] visit).
  • EditedA WOCBP must have a negative serum pregnancy test at the screening visit (Visit 1) Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:
Exclusion criteria
  • AddedParticipants are excluded from the study if any of the following criteria apply:
  • AddedHas other associated clotting disorders at the time of consent/assent.
  • AddedIs already under efanesoctocog alfa treatment.
  • EditedHas other associated clotting disorders at the time of consent/assent. Is already under efanesoctocog alfa treatment. Has a current diagnosis of an factor VIII (FVIII) inhibitor, defined as inhibitor titer ≥0.60 BU/mL.
  • AddedHas ITI within the last 2 years prior to the baseline visit (Visit 2).
  • EditedHas ITI within the last 2 years prior to the baseline visit (Visit 2). Has been enrolled in a concurrent clinical interventional study or exposed to other investigational drug(s) within 3 months prior to screening for this study.
  • AddedIs an employee or family member of the investigator or site personnel.
  • EditedIs an employee or family member of the investigator or site personnel. Is involved in a specific situation during study implementation or the course of the study that may raise ethics considerations.
  • AddedThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Oct 15, 2026
Show all 2 updates
  1. Nov 9, 2026
    5 sites added — first site in Australia
    Show 5 added (2 United States, 2 Canada, 1 Australia)
    • University of California Davis Medical Center-Site Number: 8400005 · Sacramento, United States
    • Oregon Health and Science University-Site Number: 8400002 · Portland, United States
    • Investigational Site Number : 0360001 · Murdoch, Australia
    • Investigational Site Number : 1240002 · Calgary, Canada
    • Investigational Site Number : 1240001 · St. John's, Canada
    + 1 other change: verification date
  2. Oct 15, 2026
    6 sites added, 5 sites removed. 4 sites changed recruiting status (4 now completed)
    Show 4 sites
    • Orthopedic Institute for Children- Site Number : 8400009 · Los Angeles, United StatesRecruiting→Completed
    • Investigational Site Number : 1240004 · Hamilton, CanadaRecruiting→Completed
    • Investigational Site Number : 3920002 · Hiroshima, JapanRecruiting→Completed
    • Investigational Site Number : 3920004 · Tokyo, JapanRecruiting→Completed
    Show 6 added (3 United States, 3 Taiwan)
    • Indiana Hemophilia and Thrombosis Center- Site Number : 8400006 · Indianapolis, United States
    • The Ohio State University Wexner Medical Center - CarePoint East- Site Number : 8400001 · Columbus, United States
    • Washington Center for Bleeding Disorders- Site Number : 8400008 · Seattle, United States
    • Investigational Site Number: 1580003 · Kaohsiung City, Taiwan
    • Investigational Site Number: 1580001 · Taichung, Taiwan
    • Investigational Site Number: 1580002 · Taipei, Taiwan
    Show 5 removed
    • Innovative Hematology, Inc.- Site Number : 8400006 · Indianapolis, United States
    • Ohio State University Hospital East- Site Number : 8400001 · Columbus, United States
    • Investigational Site Number : 1580003 · Kaohsiung City, Taiwan
    • Investigational Site Number : 1580001 · Taichung, Taiwan
    • Investigational Site Number : 1580002 · Taipei, Taiwan
    Eligibility 4 inclusion criteria edited, 2 added; 3 exclusion criteria edited, 6 added
    What changed in the criteria
    Inclusion criteria
    • EditedInclusion Criteria: Participant is diagnosed with moderate to severe hemophilia A (defined as less than or equal to (≤)5 percent (%) of endogenous FVIII clotting activity) at the time of consent/assent.
    • Edited*An eligible joint is a joint with existing synovial hypertrophy, as defined by a HEAD-US synovitis score of 1 or 2, considering hypertrophic synovium as an indication of the presence of synovitis Participant has received prophylactic treatment with hemophilia prophylaxis prescriptions in the last 12 months prior to the baseline visit (Visit 2).
    • AddedParticipant has received prophylactic treatment with hemophilia prophylaxis prescriptions in the last 12 months prior to the baseline visit (Visit 2).
    • AddedIs a women of nonchildbearing potential (WONCBP)
    • EditedIs a women of nonchildbearing potential (WONCBP) Is a women of childbearing potential (WOCBP) and agrees to use a highly effective contraceptive method, with a failure rate of less than (<)1 percent during the study treatment period (at least until the Week 52/ End of Treatment [EoT] visit).
    • EditedA WOCBP must have a negative serum pregnancy test at the screening visit (Visit 1) Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:
    Exclusion criteria
    • AddedParticipants are excluded from the study if any of the following criteria apply:
    • AddedHas other associated clotting disorders at the time of consent/assent.
    • AddedIs already under efanesoctocog alfa treatment.
    • EditedHas other associated clotting disorders at the time of consent/assent. Is already under efanesoctocog alfa treatment. Has a current diagnosis of an factor VIII (FVIII) inhibitor, defined as inhibitor titer ≥0.60 BU/mL.
    • AddedHas ITI within the last 2 years prior to the baseline visit (Visit 2).
    • EditedHas ITI within the last 2 years prior to the baseline visit (Visit 2). Has been enrolled in a concurrent clinical interventional study or exposed to other investigational drug(s) within 3 months prior to screening for this study.
    • AddedIs an employee or family member of the investigator or site personnel.
    • EditedIs an employee or family member of the investigator or site personnel. Is involved in a specific situation during study implementation or the course of the study that may raise ethics considerations.
    • AddedThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06941870
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Sep 23, 2025
Primary completion
Oct 25, 2027 (estimated)
Completion
Oct 25, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efanesoctocog alfa

Start the discussion